New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2013
13:05 EDTSNY, TSPTFDA doesn't require labeling changes for Intermezzo in review of sleep aids
The FDA announced earlier that it is requiring Sanofi (SNY), the manufacturer of Ambien, and some makers of other insomnia drugs that contain zolpidem, to lower the recommended dose. The FDA said the recommended bedtime dose should be lowered because new data show that blood levels in some patients may be high enough the morning after use to impair activities that require alertness, including driving. The FDA said recommended doses of Transcept Pharmaceuticals' (TSPT) Intermezzo, a lower dose zolpidem product approved for middle-of-the-night awakenings, are not changing. At the time of Intermezzo’s approval in November 2011, the label already recommended a lower dosage for women than for men, the FDA noted. In afternoon trading, shares of Transcept rose 16c, or 3.04%, to $5.43. Reference Link
News For TSPT;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2015
08:01 EDTSNYAmgen pricing for Repatha competitive with Praluent, says Piper Jaffray
After the FDA announced last night that it has approved Amgen's (AMGN) Repatha injection, Piper Jaffray analyst Joshua Schimmer said that the drug's indications seem "generally in line" with those for Praluent from Regeneron (REGN) and Sanofi (SNY). Amgen disclosed an annual WAC of $14,100 for Repatha, which the analyst notes is about $500 per year below Praluent, but Schimmer said that the actual recognized price for each will ultimately be determined by discounting. Schimmer also noted that Amgen said it is working with payers and other purchasers on "innovative pricing programs," though he is uncertain if that means the company is working on a kind of "pay per performance" scheme. The analyst, who believes the market will prove large enough for both treatments, keeps a $200 price target and Overweight rating on Amgen shares.
August 27, 2015
19:14 EDTSNYExpress Scripts to cover both Repatha, Praluent for now, Bloomberg says
Subscribe for More Information
August 20, 2015
11:33 EDTSNYLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use